Nobody starts a GLP-1 at full strength. Every medication in the class begins below its working dose and climbs a fixed ladder over weeks or months: an Ozempic prescription starts at a quarter of a milligram, a Zepbound prescription at 2.5 mg, and both may eventually sit at many times that. This staged climb is called titration, and it confuses more new patients than any other part of GLP-1 life.
Why so slow? Why does the first month feel like nothing is happening? Why did the prescriber "hold" a step? And how are you supposed to remember whether this is week two or week three at the current dose? This guide answers all of it, with every major ladder in one table you can bookmark.
Why the slow climb exists
GLP-1 medications work partly by slowing gastric emptying: food stays in the stomach longer, fullness arrives sooner and lingers. Introduced abruptly at full dose, that same effect produces the class’s signature side effects, with nausea at the front of the line. Introduced gradually, the digestive system adapts at each rung before the next one arrives. Titration is, at heart, a tolerability program: the labels space steps weeks apart because that is roughly how long adaptation takes, and nausea is typically at its worst just after an increase before fading over the following weeks.
There is a second, quieter reason for the pacing. Each step on a weekly medication takes about a month to show its full effect, because the drug accumulates toward a new steady level over roughly four to five half-lives. Judging a step after one week judges an unfinished picture; the four-week block gives both your gut and the data time to catch up.
The corollary surprises people: starting doses are not treatment doses. Ozempic’s 0.25 mg step, for example, is explicitly a non-maintenance starting dose per the prescribing information; it exists to prepare your body, not to move your weight or glucose numbers. If the first month feels underwhelming, that is the design, not a failure. Our guide to the first week on a GLP-1 covers how those early expectations should be set.
Every ladder in one place
These are the dose ladders from each product’s FDA label. Your own plan may differ, and the label is not a promise that you will climb every rung; it is the menu your prescriber orders from.
| Medication | Cadence | Dose ladder | Step timing (per label) |
|---|---|---|---|
| Ozempic (semaglutide) | Weekly injection | 0.25 → 0.5 → 1.0 → 2.0 mg | Typically every 4 weeks; 0.25 mg is a starting, non-maintenance dose |
| Wegovy (semaglutide) | Weekly injection | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg | Steps typically every 4 weeks |
| Mounjaro / Zepbound (tirzepatide) | Weekly injection | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg | Steps typically every 4 weeks |
| Rybelsus (oral semaglutide) | Daily tablet | 3 → 7 → 14 mg | 30 days at 3 mg before any increase |
| Saxenda (liraglutide) | Daily injection | 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg | Steps at weekly intervals |
| Victoza (liraglutide) | Daily injection | 0.6 → 1.2 → 1.8 mg | Prescriber-directed steps |
| Trulicity (dulaglutide) | Weekly injection | 0.75 → 1.5 → 3.0 → 4.5 mg | Prescriber-directed steps |
| Byetta (exenatide) | Twice-daily injection | 5 → 10 mcg | Prescriber-directed step |
| Adlyxin (lixisenatide) | Daily injection | 10 → 20 mcg | Prescriber-directed step |
Notice the shapes. The weekly injectables mostly move in four-week blocks, which is also roughly how long they take to settle toward a steady level after each change. The dailies move faster (Saxenda can step every week) because the shorter half-life of liraglutide reaches its new equilibrium in days, not weeks. And Rybelsus insists on a full 30 days at 3 mg, a step that exists purely for adaptation. The cadence of your ladder is not arbitrary; it mirrors the pharmacology underneath it, which our semaglutide half-life guide unpacks.
The week count is the whole game
Titration reduces your medication life to a simple pair of numbers: which step, and which week of that step. "1.0 mg, week 3 of 4" tells you and your prescriber everything about where you are and what happens next. Losing that count is how the confusion starts: people drift an extra week or two at a step because nobody was counting, or arrive at an appointment unable to say how long the current dose has actually had to work.
Counting in practice looks like this. Suppose a Mounjaro plan starts on the first Saturday of June at 2.5 mg. Four Saturday shots carry you through the first step; early July begins week 1 of 4 at 5 mg, and each later increase opens another four-week block, so by September the question "how long at 7.5?" has a one-glance answer. Now add real life: the prescriber holds the 5 mg step for two extra weeks, a vacation nudges shot day from Saturday to Monday, and suddenly the arithmetic has three moving parts. Nothing about that is complicated for software; it is exactly the kind of bookkeeping that memory silently mangles by autumn.
Paper can track this; software is simply better at it. A tracker with real titration ladders knows your plan, counts the weeks at each step automatically, and turns dose logging into one tap on the amount you actually take. When the prescriber asks how many weeks you have been at the current step, the answer is on the screen instead of reconstructed from pharmacy receipts.
GLP 1 Tracker AppFree on the App Store. Every ladder above ships as a preset, with automatic week counts and shot-day reminders.
Get the app
Holds, pauses and partial climbs are normal
The label’s ladder is the fastest allowed climb, not a mandate. In practice, prescribers routinely hold a patient at a step for extra weeks when side effects need more time to settle, and many people never visit the top rung at all: maintenance can land mid-ladder if that is where results and tolerability balance. Wegovy’s five steps, for instance, exist so that 2.4 mg is approached gently, but the journey there is individual; our Wegovy schedule guide walks that specific ladder month by month.
Steps can also go down. When an increase proves rough, prescribers sometimes move a patient back a rung and retry the climb later, once things settle. None of this is failure; it is the system working as designed. The log’s job during a hold or a step back is to capture the why: a side effect diary with severity shows the prescriber exactly what the last increase did, which is the evidence behind the next decision. Our guide to tracking side effects covers what makes that diary useful.
When missed doses tangle the ladder
Titration and missed doses interact in one important way: a long enough gap can send you back down. Wegovy’s label says that missing two or more consecutive doses may mean restarting or re-titrating, and Saxenda’s says that after more than three days off, the prescriber may restart at 0.6 mg. The logic is the same as the ladder itself: after a gap, your body has partially de-adapted, and rejoining at a high dose can bring the full force of the side effects the climb existed to avoid.
The practical takeaway is that an accurate dose log protects your place on the ladder. Knowing precisely when the last dose happened tells you and your prescriber whether a late dose fits inside the official windows or whether the re-titration conversation applies. The exact windows for every medication are in our missed dose guide.
Never self-adjust, and why that is rule one
Everything above points to one rule that deserves its own section: the ladder is climbed with your prescriber, never alone. Doubling up after a missed dose, skipping a rung because the current one feels easy, stretching a pen’s doses because of a refill gap, or borrowing a step from someone else’s plan all break the adaptation logic the schedule is built on, and some collide directly with safety guidance in the labels. The same rule applies to software: a tracker should record your doses and count your weeks, and any app that suggests what dose to take next is overstepping. GLP 1 Tracker App never advises doses, by design.
What you can do is come to each appointment with the ladder’s paper trail: doses logged on time, weeks counted, side effects rated. Those records are how holds get shortened, steps get timed well, and the climb fits your life instead of the other way around.
The takeaway
Titration is tolerability engineering: every GLP-1 starts low and climbs on a schedule that gives your digestive system time to adapt, and the ladders above are the full map. Your job is not to manage the climb; it is to know exactly where you are on it. Log each dose, let the week count run, note how each step treats you, and leave every rung decision to the person holding the prescription pad.
Frequently asked questions
Why do GLP-1 doses start so low?
Tolerability. GLP-1 medications slow gastric emptying, and introduced abruptly at full dose that effect produces the class’s signature side effects, nausea first. Starting low and climbing in spaced steps gives the digestive system time to adapt at each rung. Starting doses are not treatment doses: Ozempic’s 0.25 mg step, per the prescribing information, is a non-maintenance starting dose that exists to prepare your body, not to move your numbers.
How long do you stay at each dose of a GLP-1?
The weekly injectables (Ozempic, Wegovy, Mounjaro, Zepbound) typically move in four-week blocks per their labels, which is also roughly how long each new dose takes to settle toward a steady level. Rybelsus requires 30 days at 3 mg before any increase, and Saxenda can step weekly. Prescribers also routinely hold a step longer when side effects need time, so your plan may move more slowly than the label’s fastest climb.
Do I have to reach the highest dose of my GLP-1?
No. The label’s ladder is the fastest allowed climb, not a mandate. Many people never visit the top rung; maintenance can land mid-ladder wherever results and tolerability balance. Steps can also go down: when an increase proves rough, prescribers sometimes move back a rung and retry later. Where your climb settles is a decision you and your prescriber make together, informed by your log.
Can I increase my GLP-1 dose myself if I feel fine?
No. The ladder is climbed with your prescriber, never alone. Skipping a rung, doubling up after a missed dose, or borrowing a step from someone else’s plan breaks the adaptation logic the schedule is built on and can collide with safety guidance in the labels. What you control is the record: doses logged on time, weeks counted, side effects rated. That evidence is what shapes each step decision.
What happens to my titration schedule if I miss doses?
A long enough gap can send you back down the ladder. Wegovy’s label says missing two or more consecutive doses may mean re-titrating, and Saxenda’s says that after more than three days off, the prescriber may restart at 0.6 mg. After a gap the body partially de-adapts, so rejoining at a high dose invites the side effects the climb exists to avoid. An accurate dose log shows which rules apply to your situation.